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Rationale: A number of randomised controlled trials have indicated that multivitamin/mineral 
supplementation for a period of four weeks or greater can enhance mood and cognition. To date, no 
studies have investigated whether a single multivitamin dose can benefit mental function in older 
adults.  
Methodology: This study investigated the acute effects of a single multivitamin, mineral and herbal 
(MVMH) supplement versus placebo on self-ratings of mood and the performance of an effortful 
computerised cognitive battery in a sample of 76 healthy women aged 50- 75 years. Mood was 
assessed using the Depression Anxiety Stress Scale (DASS), State Trait Anxiety Inventory – State 
Anxiety Scale and Visual Analogue Scales (VAS). Mood was rated at one hour post-supplementation 
and again after the competition of the cognitive assessments at 2 hours post supplementation.  
Results: It was demonstrated that the MVMH supplement improved overall DASS mood ratings; 
however the most prominent effects appeared to be a reduction in ratings of perceived mental 
stress. These findings were confirmed using Visual Analogue Scales, with these measures also 
demonstrating MVMH-related increased ratings of calmness. There were no benefits of the MVMH 
to mood ratings of depression and performance was not enhanced on the cognitive battery.    
Conclusions: Supplementation with a single multivitamin, mineral and herbal supplement reduces 
stress several hours after intake in healthy older people.  
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 37 
Abstract 38 
Rationale: A number of randomised controlled trials have indicated that multivitamin/mineral 39 
supplementation for a period of four weeks or greater can enhance mood and cognition. To date, no 40 
studies have investigated whether a single multivitamin dose can benefit mental function in older 41 
adults.  42 
Methodology: This study investigated the acute effects of a single multivitamin, mineral and herbal 43 
(MVMH) supplement versus placebo on self-ratings of mood and the performance of an effortful 44 
computerised cognitive battery in a sample of 76 healthy women aged 50- 75 years. Mood was 45 
assessed using the Depression Anxiety Stress Scale (DASS), State Trait Anxiety Inventory – State 46 
Anxiety Scale and Visual Analogue Scales (VAS). Mood was rated at one hour post-supplementation 47 
and again after the competition of the cognitive assessments at 2 hours post supplementation.  48 
Results: It was demonstrated that the MVMH supplement improved overall DASS mood ratings; 49 
however the most prominent effects appeared to be a reduction in ratings of perceived mental 50 
stress. These findings were confirmed using Visual Analogue Scales, with these measures also 51 
demonstrating MVMH-related increased ratings of calmness. There were no benefits of the MVMH 52 
to mood ratings of depression and performance was not enhanced on the cognitive battery.    53 
Conclusions: Supplementation with a single multivitamin, mineral and herbal supplement reduces 54 
stress several hours after intake in healthy older people.  55 
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 77 
Introduction 78 
A growing literature has indicated that chronic multivitamin supplementation can benefit cognition 79 
(Grima et al. 2012) and mood (Long and Benton 2013). Randomised controlled trials have 80 
demonstrated that supplementation with multivitamins containing minerals and herbs, over a 81 
period of two to four months, can enhance various domains of memory in those over the age of 50 82 
(Harris et al. 2012; Macpherson et al. 2012; Summers et al. 2010). In men aged 50-69 years, eight 83 
weeks multivitamin/mineral and herbal (MVMH) supplementation has been shown to reduce 84 
symptoms of mood disorder, problems with day-to-day functioning, and increase positive mood 85 
experience (Harris et al. 2011). Findings of elevated positive mood associated with chronic 86 
multivitamin use has been confirmed in a recent meta-analysis (Long and Benton 2013) which 87 
revealed that across eight studies of non-clinical samples, multivitamin supplements improved mild 88 
psychiatric symptoms and facets of mood including stress and subclinical anxiety.  89 
Whilst behavioural effects of multivitamins have been generally observed in studies greater than 90 
four weeks duration (Grima et al. 2012), very few investigations have focussed on the possibility that 91 
multivitamin supplements may influence cognition after a single dose. The first of these studies 92 
identified improvements to memory and attention, but not mood,  in children aged 8 to 14 years, 93 
three hours after the administration of a single multivitamin  (Haskell et al. 2008). A more recent 94 
study, conducted in healthy adults aged 21- 39 years, utilised brain imaging techniques to investigate 95 
the acute effects of multivitamins on neurocognitive function (White et al. 2014). Results from this 96 
trial revealed that a single multivitamin, 90 minutes post-dose, increased activation in task-relevant, 97 
prefrontal brain regions during the completion of a continuous performance attention task. These 98 
findings provide evidence that multivitamins can exert effects on the central nervous system within 99 
several hours of ingestion.   100 
Previously, mood benefits of an acute multivitamin dose have only been identified for supplements 101 
containing the plant extract guarana, and not for standard multivitamin preparations (Haskell et al. 102 
2008; Kennedy et al. 2008; Scholey et al. 2013). Due to the small number of studies in this area, it is 103 
not certain whether these mood effects can be solely attributed to the caffeine content of the 104 
guarana extract. Furthermore as these studies are limited to young adults and children, it is not 105 
known whether a single multivitamin dose would benefit cognition or mood in older people. We 106 
have previously suggested that chronic multivitamin use may be expected to exert greater effects in 107 
older people who are at great risk of nutritional deficiency and cognitive decline (Macpherson et al. 108 
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2012; Pipingas et al. 2014), but whether the same benefits would be observed following the 109 
administration of a single supplement has not been explored in older adults.  110 
The objective of the current study was to explore the mood and cognitive profile of any acute 111 
multivitamin effects in women aged 50 to 75 years of age, free from clinical mood disturbances.   112 
Secondary results from a four week randomised controlled trial are reported from the acute testing 113 
session 1-2 hours following the administration of a single MVMH supplement or placebo. Mood 114 
measures were selected which have previously demonstrated sensitivity to multivitamin 115 
supplementation over longer time durations (Harris et al. 2011; Long and Benton 2013; Pipingas et 116 
al. 2013). Mood ratings were assessed at 1 hour post dose, and again at 2 hours post dose after 117 
participants had completed an effortful cognitive battery.  118 
Methods 119 
Study design and treatment  120 
This study adopted a double-blind, placebo-controlled, randomised design. Baseline mood was 121 
assessed prior to and after completing a cognitive battery. This procedure was repeated at 1 hour 122 
post dose. The MVMH treatment was the Swisse Women’s 50+ Ultivite supplement or a placebo 123 
matched for appearance and taste. The supplement was administered orally in tablet form. The full 124 
ingredients of the Swisse Women’s 50+ Ultivite supplement are published elsewhere (Macpherson 125 
et al. 2012). In brief the MVMH contains 14 vitamins, 11 minerals, 3 strains of probiotics and 18 126 
herbal extracts.  The Swisse Women’s 50+ Ultivite supplement contains folic acid, vitamins A, B1, B2, 127 
B5, B6, B12, C, E and zinc at levels above the recommended daily intake (RDI). Levels of B3, D3, 128 
calcium and magnesium are below the RDI. This study was approved by the Swinburne University 129 
Human Research Ethics Committee (SUHREC) and was carried out in accordance with the 130 
Declaration of Helsinki. The trial is registered on the Australian New Zealand Clinical Trials Registry 131 
(ACTRN12613001087741).  132 
 133 
Participants 134 
Participants were 76 women aged 50- 75 years (M = 63.6 years, SD = 6.4 years) who were not 135 
engaged in full time employment.  All participants were non-smokers, with no history of diabetes, 136 
cardiovascular disease, dementia, stroke, other neurological conditions, head trauma, alcohol abuse, 137 
clinically diagnosed anxiety, depression, psychiatric disorders, and were not currently using anti-138 
depressant medication, anti-anxiety medication, high dose anti-coagulants, all anti-cholinergic drugs 139 
or acetylcholinesterase inhibitors. Participants were required to abstain from supplementation with 140 
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vitamin E, multivitamins, B vitamin complex, ginkgo biloba, fish oil, and St John’s Wort for 4 weeks 141 
preceding the study visit.  142 
Procedure  143 
On the testing day, participants were requested to consume their ‘usual’ breakfast and to refrain 144 
from caffeine consumption. Participants attended the laboratory between 0900 and 1100 hours. All 145 
participants signed an informed consent form and completed a medical health questionnaire prior to 146 
enrolment in the study. The mini mental state examination (MMSE) (Folstein et al. 1975) and the 147 
National Adult Reading Test- Revised (NART-R) (Nelson and Willison 1991) were administered to 148 
provide an estimate of global cognitive performance and IQ, respectively. After completing baseline 149 
mood and cognitive measures, participants were randomised to receive the MVMH or placebo. 150 
Participants were provided with one supplement to take with a glass of water and a slice of 151 
wholemeal toast with a choice of two spreads. Following a delay of 1 hour, mood measures were 152 
repeated followed by the cognitive battery. Mood measures were repeated a second time after the 153 
cognitive measures, corresponding 2 hours post multivitamin dose. The testing procedure is 154 
illustrated in Figure 1.  The DASS and STAI-S measures were completed using pen and paper 155 
versions. The Bond lader and VAS measures were completed using mobile phone devices to enable 156 
laboratory and in home assessments (results for longer term supplementation effects and in home 157 
assessments presented elsewhere).  158 
Outcomes 159 
All acute outcomes were secondary outcomes from the Behavioural Effects of Multivitamins 160 
Supplements (BEMS) study. The primary outcome was mood changes over a longer four week period 161 
(details of the four week methodology and findings presented elsewhere). 162 
Mood ratings 163 
Depression Anxiety Stress Scale (DASS) (Lovibond and Lovibond 1995): The DASS is a brief 164 
questionnaire comprising 21 items which form depression, anxiety and stress subscales (Lovibond SH 165 
1995). Responses to each item are made on a 4-point scale from 0 to 3, producing a maximal score 166 
of 63. Higher scores indicate more symptoms of dysphoric mood, whilst a score of 0 indicates the 167 
absence of disturbed mood symptoms. To facilitate the identification of acute mood changes, 168 
individuals were required to rate how they were feeling “right now”.   169 
 170 
State Trait Anxiety Inventory (STAI) – State Anxiety Scale (Speilberger et al. 1969): 171 
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The State Anxiety Scale from the STAI consists of 20 items which assesses an individual’s current 172 
state of anxiety, asking how respondents feel “right now”.   The State Anxiety Scale assesses 173 
intensity of current feelings of stress on a 4-point scale from 1 (not at all) to 4 (very much so). Scores 174 
range from 20 to 80 with higher scores indicating greater anxiety.  175 
 176 
Bond-Lader Visual Analogue Scale (VAS) (Bond and Lader 1974): The Bond-Lader mood scales require 177 
participants to mark the appropriate position on a horizontal line. The scales comprise 16 lines 178 
anchored at either end by adjective pairs e.g. happy-sad. Participants are required to mark their 179 
current subjective state between the antonyms on the line and each line is scored as the percentage 180 
of the total distance from the negative anchor (i.e. higher score indicate more positive mood state). 181 
Three subscales are calculated on the basis of scores from the 16 adjective pairs, representing the 182 
factors “alert”, “content” and “calm”.  183 
 184 
Stress, Anxiety, Concentration, Physical Fatigue and Mental Fatigue Visual Analogue scales (VAS): 185 
Each Visual Analogue Scale consists of a single unmarked 100 mm line with end-points labelled ‘Not 186 
at all’ and ‘Very much so’. Individuals are instructed to indicate on the line how they feel at that 187 
moment in time. Each scale gives a single subjective score between 0 and 100, with lower scores 188 
indicative of more desirable mood states on the mood scales and higher energy levels on the fatigue 189 
scales. Separate scales were used to assess stress, anxiety, concentration, physical fatigue and 190 
mental fatigue.  191 
 192 
Cognition 193 
Swinburne University Computerised Cognitive Assessment Battery (SUCCAB) 194 
The SUCCAB stimuli were presented via PC using the E-Prime 2.0 software (Psychology Software 195 
Tools, Pittsburgh, PA) and a hand held button box was used to deliver all responses.  Tasks from the 196 
SUCCAB have been demonstrated to be sensitive to the effects of chronic MVMH supplementation 197 
in older people (Harris et al. 2012; Macpherson et al. 2012). A practice trial was performed 198 
immediately prior to each task. An alternate task version was used for the acute 1 hour post 199 
treatment time point. The following tasks were undertaken:  200 
Simple reaction time:  Speeded response to a white square.  201 
Stroop Congruent: Response to the words RED, YELLOW, GREEN and BLUE presented in the same 202 
colour as the written word. 203 
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Stroop Incongruent: Response to the words RED, YELLOW, GREEN and BLUE presented in a different 204 
colour to the written word. Stroop Interference score was then calculated from Stroop congruent 205 
reaction time subtracted from Stroop incongruent reaction time. 206 
Immediate and delayed recognition memory:  Immediate of a series of abstract patterns and delayed 207 
recognition at the end of the test battery (30-min delay).  208 
Contextual recognition memory: Recognition of the location of pictures of everyday items presented 209 
at one of four locations on the computer screen.  210 
Working memory: The location of 6 white squares in a 4X4 grid was memorised. Participants 211 
indicated if squares presented individually were shown in the original array.    212 
Analysis 213 
Baseline group differences on all measures were examined using independent group t tests. Mixed 214 
design, analysis of variance (ANOVA) models were used to examine the effects of the MVMH on 215 
mood and cognition.  To determine whether mood effects were most prominent before or after 216 
completing the effortful cognitive assessments, mixed design  ANOVAS were conducted for the 217 
DASS, STAI and all VAS measures using 2 (Treatment: Multivitamin, Placebo) x 2 (Time: pre-dose, 218 
post-dose) x 2 (Task:  pre cognitive task performance, post cognitive task performance). On the 219 
identification of a significant Treatment x Time interaction, post hoc bonferroni tests were used to 220 
examine the difference between baseline and post-treatment measures for each group individually.  221 
A series of 2 (Treatment: Multivitamin, Placebo) x 2 (Time: baseline, post treatment) mixed design, 222 
repeated measures ANOVAs were used to examine the effects of the MVMH on the cognitive 223 
measures. Statistical significance was set at p <.05.   224 
Results 225 
Demographics and baseline performance 226 
A total of 39 participants were allocated the multivitamin and 37 allocated placebo. Independent 227 
groups t-tests indicated the groups did not differ significantly in terms of age (multivitamin M = 64.4, 228 
placebo M = 62.8, p = .28) or MMSE score (multivitamin M = 29.3, placebo M = 29.4, p = .75). The 229 
multivitamin group had completed significantly greater years of education (multivitamin M = 17.0, 230 
placebo M = 15.4, p = .03) and had a higher NART IQ score (multivitamin M = 119, placebo M = 116, 231 
p = .02). The most commonly reported medications were cardiac medications (multivitamin n = 13, 232 
placebo n = 10) and arthritis medications (multivitamin n = 3, placebo n = 4). Independent groups t-233 
tests indicated there were no significant baseline differences between the multivitamin and placebo 234 
groups on any of the mood or SUCCAB outcome measures. Mean correct was over 95% for the 235 
simple reaction time and stroop measures indicating these tasks were performed at ceiling, 236 
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therefore only response time was examined as an outcome for these tasks. A log transformation was 237 
applied to the DASS total score, anxiety and depression subscale scores to correct for a positive 238 
skew. Means and standard deviations for each measure are shown in Table 1 and Table 2.  239 
 240 
Acute mood effects of the multivitamin  241 
Depression Anxiety Stress Scale: A significant Time x Treatment interaction for the DASS total score 242 
was identified (F (1,72) =  5.54, p = .02, η2 = 0.07 ). Post hoc bonferroni tests indicated there was a 243 
significant reduction in DASS score for the multivitamin group only (p < .001). A significant Time x 244 
Treatment interaction for the DASS stress score was identified (F (1,72) =  6.97, p = .01, η2 = 0.09 ). 245 
Post hoc bonferroni tests indicated there was a significant reduction in DASS score for the 246 
multivitamin group only (p <.001). Change from baseline DASS scores are shown in Figure 2 to 247 
demonstrate the magnitude of these changes.  248 
Visual Analogue Scales: A significant Time x Treatment interaction for the Bond Lader VAS calmness 249 
score was identified (F (1,71) =  5.37, p = .02, η2 = 0.07 ). Post hoc bonferroni tests indicated there 250 
was a significant increase in calmness for the multivitamin group only (p = .003). A significant Time x 251 
Treatment interaction for the VAS stress score was identified (F (1,71) =  7.44, p = .008, η2 = 0.10 ). 252 
Post hoc bonferroni tests indicated there was a significant reduction in VAS stress rating for the 253 
multivitamin group only (p = .001). A significant Time x Treatment interaction for the VAS anxiety 254 
score was identified (F (1,71) =  4.38, p = .04, η2 = 0.06 ). Post hoc bonferroni tests indicated the 255 
reduction in VAS anxiety did not reach statistical significance for either group.  256 
Controlling for group differences in years of education and NART-IQ did not alter the statistical 257 
significance of any mood ratings, with the exception of the VAS rating of anxiety which was 258 
diminished to a trend following adjustment for baseline differences in IQ (1,69) = 3.24, p = .08, η2 259 
=.05). Main effects of Time are shown in Table 2. There were no significant main effects of 260 
Treatment identified for any mood measures.  261 
Effects of the cognitive battery on mood ratings 262 
As shown in Table 2, a significant main effect of Task was identified for a number of VAS ratings, 263 
indicating that participants reported a reduction in alertness, contentedness, calmness, higher levels 264 
of stress, anxiety, greater mental fatigue, physical fatigue and reduced concentration after 265 
completing the cognitive battery.   266 
 267 
Acute cognitive effects of the multivitamin 268 
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There were no significant Time x Treatment interactions for the cognitive measures. As shown in 269 
Table 2, a performance on a number of SUCCAB measures improved significantly from baseline to 270 
post-treatment, regardless of which treatment was administered. There were no other significant 271 
main effects identified for the SUCCAB measures. Controlling for group differences in years of 272 
education and NART-IQ did not alter the statistical significance of any cognitive measures.  273 
 274 
Discussion 275 
 276 
The results of the present study indicated that MVMH supplementation can benefit mood 1-2 hours 277 
post dose. Specifically, it was found that taking a single multivitamin improved overall mood ratings 278 
on the DASS and this effect appeared to be driven by a significant reduction in stress ratings. The 279 
MVMH was associated with decreased ratings of stress and increased ratings of calmness on the 280 
visual analogue scales. There were no benefits to aspects of mood including depression or ratings of 281 
physical and mental fatigue at any time point. In contrast to chronic studies in older people, which 282 
have shown improvements to memory (Harris et al. 2012; Macpherson et al. 2012; Summers et al. 283 
2010), a single MVMH dose did not exert any effects on cognitive performance.  284 
The potential for a single multivitamin dose to modulate mood and cognition has not previously 285 
been investigated in an older sample. Similar to a four week study in men of a comparable age range 286 
(Harris et al. 2011), the current study identified improvements on the overall DASS score following 287 
MVMH administration. In this study, the acute mood benefits were most apparent on ratings of 288 
perceived stress, with two measures of stress and a measure of calmness and anxiety all showing an 289 
improvement following the MVMH dose. However, it must be noted that the effect of the 290 
multivitamin on anxiety was attenuated when controlling for baseline group differences in IQ. 291 
Relative to assessments taken both before, and after completing the effortful cognitive assessments, 292 
the MVMH reduced DASS stress score by over 30%. By contrast, stress reductions attributed to the 293 
placebo were in the order of 11% and less. Interestingly, stress is the mood facet which has also 294 
been reported to show the greatest improvements following chronic multivitamin supplementation 295 
(Long and Benton 2013). Benefits to stress ratings following ≤ one month of multivitamins containing 296 
high dose vitamin B have been observed in non-clinical samples in a number of randomised 297 
controlled trials (Carroll et al. 2000; Kennedy et al. 2010; Schlebusch et al. 2000; Stough et al. 2011). 298 
Whilst lower dose B vitamin supplements have been associated with both positive (Harris et al. 299 
2011) and negative findings (Haskell et al. 2010). 300 
Mood benefits of chronic multivitamin supplementation have largely been attributed to folate, B6 301 
and B12, which have important roles in neurotransmitter synthesis (serotonin, noradrenaline and 302 
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dopamine) (Huskisson et al. 2007), and in the remethylation of homocysteine to SAMe (Bottiglieri 303 
2005).  For instance, B12 and folate deficiencies have been associated with higher levels of 304 
depression (Alpert et al. 2000; Baldewicz et al. 2000; Tolmunen et al. 2003).  The potential of folate 305 
in the reduction of clinical mood states is well documented (Bottiglieri 2005), and may also have an 306 
effect in non-clinical populations (Malouf et al. 2003). Additionally, poorer mood has been 307 
associated with lower levels of vitamin D, zinc and selenium (Benton 2002; Levenson 2006; Wilkins 308 
et al. 2006). Thiamine and the minerals calcium, magnesium and iron have also been postulated to 309 
influence mood through a number of biological pathways (Kaplan et al. 2007).  310 
To date, the mechanism regarding acute effects of multivitamin supplementation on mood is 311 
unexplored in the literature.  Some have suggested that improved vascular endothelial function and 312 
improvements in mitochondrial function as a potential mechanism for acute cognitive improvements 313 
(Kennedy et al. 2008).  For instance, improved vasodilation and blood flow to the brain, results in the 314 
increased delivery of metabolites to active tissue, leading to improved task performance (Scholey et 315 
al. 2001). Without the measurement of blood metabolites in this study, potential mechanisms can 316 
only be speculated. Bioavailability data has demonstrated that when taken in tablet form, 1000 µg of 317 
folic acid  leads to peak serum folate levels two hours after ingestion, with levels approaching the 318 
peak even at one hour post dose (Maki et al. 2012). A lower level of 500µg folic acid was included in 319 
the MVMH treatment examined in the current study, however the timeframe for mood benefits 320 
appears to be consistent with the peak folate concentration described by Maki et al. (2012).   321 
In the current study we examined whether any mood effects were strongest following the 322 
completion of an effortful cognitive battery, which was demonstrated to increase anxiety, stress, 323 
mental fatigue and physical fatigue, whilst reducing alertness, calmness and concentration. Acute 324 
psychological stressors, even for short durations can induce cardiovascular, digestive, and immune 325 
system changes and increase circulating levels of the hormone cortisol, due to activation of the 326 
hypothalamic-pituitary-adrenal  (HPA) axis (Kemeny 2003). It has also been suggested that 327 
psychological stress impairs methylation reactions, resulting in alterations to the availability of  328 
nutrients for neurotransmitter synthesis and function (Kaplan et al. 2007). Given the MVMH 329 
contained a range of B vitamins (including vitamin B6, B12 and folate at levels equivalent to the 330 
recommended daily intake) it may have been anticipated that any stress induced by the cognitive 331 
assessments would be offset by the supplement. Instead, the results provided evidence of a general 332 
reduction to stress levels which were not indicative of protection against short term increases to 333 
stress levels. A limitation of this study was that mood assessments were only taken 1 and 2 hours 334 
post dose therefore it is not known how long any benefits were sustained.    335 
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It is not clear why mood, but not cognitive benefits were observed in this study, as cognitive 336 
improvements and brain functional changes have been identified several hours after a single 337 
multivitamin dose in younger participant groups (Haskell et al. 2008; White et al. 2014). The same 338 
working memory (Macpherson et al. 2012) and episodic memory measures (Harris et al. 2012) used 339 
in the current study have previously demonstrated benefits following two to four months MVMH 340 
supplementation, indicating the assessments used in this study were suitable to detect 341 
improvements due to multivitamin supplementation.  It may be that in an older sample, who are 342 
more prone to nutritional insufficiencies (Brownie 2006), our previously reported cognitive benefits 343 
of multivitamins (Harris et al. 2012; Macpherson et al. 2012) are due to a cumulative effect of 344 
improving nutritional status over time. More studies are required across both males and females to 345 
confirm or negate this premise, particularly as the current study solely focussed on women, and 346 
cannot confirm whether males would demonstrate the same acute response following multivitamin 347 
intake.  A final note of consideration is that some chronic studies which have identified mood 348 
benefits of multivitamins have not reported whether participants consumed the  supplement on the 349 
day of post-treatment testing (Carroll et al. 2000; Kennedy et al. 2010; Stough et al. 2011). This gives 350 
rise to the possibility that the stress reductions reported in these trials may be due to acute effects 351 
of multivitamins, if participants did not abstain from supplementation on the day of post-treatment 352 
assessments. Findings from the current study suggest that mood may be elevated for several hours 353 
following multivitamin intake.  Therefore the timing of supplement intake may be an important 354 
methodological consideration when comparing results across different trials.   355 
In summary, findings from this study indicate that there are acute mood, but not cognitive effects of 356 
multivitamin supplements.  Specifically, in healthy older women a single multivitamin, mineral and 357 
herbal dose may lead to general mood enhancements, predominantly by reducing stress levels.    358 
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Table 1. Mean and standard deviations (SD) for the mood assessments, with p values shown for 460 
the Main Effects of Task (pre and post battery) and Time (pre and post dose) and Time x 461 
Treatment Interaction. 462 
Mood Measure Treatment    Baseline      Post Dose           Time  Task         Interaction 
 Group N Mean (SD) Mean (SD) p p p 
DASS        
Total  (pre battery) Multivitamin 38 10.4 (12.2) 6.7 (9.9) <.001*** .13 .02* 
 Placebo 36 7.6 (9.9) 6.4 (8.5)    
Total (post battery) Multivitamin 38 10.1 (10.6) 6.7 (8.8)    
 Placebo 36 8.3 (9.9) 7.4 (10.7)    
Depression (pre battery) Multivitamin 38 2.4 (4.3) 1.6 (3.2) .002** .50 .32 
 Placebo 36 1.6 (3.5) 1.2 (3.1)    
Depression (post battery) Multivitamin 38 2.0 (3.8) 1.1 (2.7)    
 Placebo 36 1.7 (3.5) 1.6 (4.4)    
Anxiety (pre battery) Multivitamin 38 2.1 (3.5) 1.3 (2.3) .02* .97 .23 
 Placebo 36 1.5 (2.7) 1.3 (1.9)    
Anxiety (post battery) Multivitamin 38 1.8 (2.4) 1.4 (2.6)    
 Placebo 36 1.9 (2.9) 1.2 (2.2)    
Stress (pre battery) Multivitamin 38 5.8 (5.8) 3.8 (5.3) <.001*** .06 .01* 
 Placebo 36 4.4 (5.0) 3.9 (5.3)    
Stress (post battery) Multivitamin 38 6.3 (5.9) 4.2 (5.1)    
 Placebo 36 4.7 (5.0) 4.6 (5.5)    
VAS        
Alert  (pre battery) Multivitamin 37 68.1 (18.0) 68.2 (19.0) .14 <.001*** .31 
 Placebo 36 72.5 (15.3) 71.5 (17.4)    
Alert (post battery) Multivitamin 37 57.7 (18.0) 56.5 (18.1)    
 Placebo 36 61.0 (15.6)  56.6 (15.9)    
Content (pre battery) Multivitamin 37 77.1 (17.3) 78.8 (15.1) .98 <.001*** .11 
 Placebo 36 83.0 (14.5) 83.5 (16.3)    
Content (post battery) Multivitamin 37 64.9 (17.3) 66.0 (16.1)    
 Placebo 36 72.5 (16.4) 69.2 (15.8)    
Calm (pre battery) Multivitamin 37 66.5 (21.7) 74.3 (17.4) .04* <.001*** .02* 
 Placebo 36 75.9(17.5) 75.6 (23.3)    
Calm (post battery) Multivitamin 37 55.6 (19.1) 59.7 (19.1)    
 Placebo 36 63.5 (20.9) 63.2 (18.2)    
Stress (pre battery) Multivitamin 37 23.9 (24.4) 15.4 (17.9) .06 <.001*** .008** 
 Placebo 36 14.3 (17.7) 15.1 (20.3)    
Stress (post battery) Multivitamin 37 43.7 (23.7) 35.9 (17.9)    
 Placebo 36 34.2 (23.8) 36.2 (23.6)    
Anxiety (pre battery) Multivitamin 37 18.2 (22.1) 14.1 (14.5) .95 <.001*** .04* 
 Placebo 36 13.9 (19.1) 15.9 (22.3)    
Anxiety (post battery) Multivitamin 37 31.5 (22.1) 29.4 (16.0)    
 Placebo 36 29.4 (20.9) 33.2 (23.3)    
Concentration (pre battery) Multivitamin 37 65.7 (29.0)  59.8 (26.1) .19 <.001*** .83 
 Placebo 36 63.8 (26.7) 60.8 (27.1)    
Concentration (post 
battery) 
Multivitamin 37 54.7 (25.6) 53.6 (21.2) 
  
 
 Placebo 36 56.9 (20.9) 54.9 (19.9)    
Mental Fatigue (pre battery) Multivitamin 38 23.1 (24.0) 30.3 (24.3) .003** <.001*** .97 
 Placebo 36 22.4 (22.0) 27.1 (23.6)    
Mental Fatigue (post  Multivitamin 38 43.4 (23.7) 48.3 (20.4)    
battery) Placebo 36 41.9 (21.0) 49.1 (20.5)    
Physical Fatigue (pre  Multivitamin 37 21.3 (23.3)  27.0 (23.4) .01* <.001*** .35 
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battery) Placebo 36 16.7 (18.9) 22.6 (20.2)    
Physical Fatigue (post Multivitamin 37 36.4 (22.7) 35.5 (20.7)    
battery) Placebo 36 27.7 (16.8) 32.0 (19.3)    
STAI - S        
STAI (pre battery) Multivitamin 39 33.2 (10.8) 30.3 (8.0) .001** <.001*** .24 
 Placebo 36 30.5 (9.0) 28.7 (9.5)    
STAI (post battery) Multivitamin 39 35.5 (11.4) 32.6 (9.4)    
 Placebo 36 32.6 (12.0) 31.4 (9.9)    
DASS = Depression Anxiety Stress Scale 463 
VAS = Visual Analouge Scale 464 
STAI - S = State trait anxiety inventory - State  465 
Bold font indicates a significant Time x Treatment interaction  * p <.05 level, ** p <.01 level, *** p<.001 level 466 
 467 
 468 
 469 
Figure 2. Change from baseline scores for the Depression Anxiety Stress Scale (DASS) total score 470 
and DASS stress subscale for mood ratings prior to, and after performance of the effortful 471 
cognitive battery 472 
 473 
 474 
Table 2. Mean and standard deviations (SD) for the cognitive assessments, with p values shown for 475 
the Main Effect of Time (pre and post dose) and the Time x Treatment Interaction  476 
 SUCCAB Treatment    Baseline      Post Dose           Time                                              Interaction
Task Group N Mean (SD) Mean (SD) p p 
Simple Reaction rt Multivitamin 37 320 (107) 332 (104) .94 0.38 
 Placebo 36 311 (82) 301 (35)   
Stroop Congruent rt Multivitamin 39 795 (114) 759 (124) <.001*** 0.97 
 Placebo 37 766(109) 731 (102)   
Stroop Incongruent rt Multivitamin 37 898 (131) 909 (146) .29 0.99 
 Placebo 35 877 (108) 889 (123)   
Stroop Interference rt Multivitamin 37 104 (69) 152 (82) <.001*** 0.40 
 Placebo 34 118 (100) 149 (89)   
Contextual Recognition rt Multivitamin 35 1019 (97) 1022 (94) .39 0.58 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
16 
 
 Placebo 36 995 (106) 1013 (121)   
Contextual Recognition % Multivitamin 35 79.3 (14.1) 81.6 (12.1) .23 0.98 
 Placebo 35 77.1 (15.1) 79.4 (13.1)   
Immediate Recognition rt Multivitamin 39 1015 (111) 1014 (115) .04* 0.06 
 Placebo 35 1036 (136) 990 (112)   
Immediate Recognition % Multivitamin 39 71.0 (12.9) 76.7 (11.0) <.001*** 0.71 
 Placebo 35 70.8 (12.1) 77.6 (12.1)   
Delayed Recognition rt Multivitamin 37 1017 (86) 1009 (114) .24 0.64 
 Placebo 36 1000 (88) 982 (106)   
Delayed Recognition % Multivitamin 37 69.4 (14.3) 73.6 (12.4) .01* 0.56 
 Placebo 36 70.5 (10.6) 73.0 (12.4)   
Working Memory  rt Multivitamin 39 1056 (147) 1020 (154) .03* 0.70 
 Placebo 36 1029 (131) 994 (125)   
Working Memory  % Multivitamin 39 69.8 (15.0) 72.8 (14.3) .01** 0.58 
 Placebo 37 67.3 (15.6) 72.0 (13.0)   
* p <.05 level, ** p <.01 level, *** p<.001 level 477 
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